New paper below. -Patrick
ncbi.nlm.nih.gov/pubmed/289...
Oncotarget. 2017 May 19;8(34):57782-57799. doi: 10.18632/oncotarget.17997. eCollection 2017 Aug 22.
Vitamin K and its analogs: Potential avenues for prostate cancer management.
Dasari S1, Ali SM1, Zheng G1, Chen A1, Dontaraju VS2, Bosland MC3, Kajdacsy-Balla A3, Munirathinam G1.
Author information
Abstract
Epidemiological studies have demonstrated a relationship between cancer incidence and dietary habits. Especially intake of certain essential nutrients like vitamins has been shown to be beneficial in experimental studies and some clinical trials. Vitamin K (VK) is an essential nutrient involved in the blood clotting cascade, and there are considerable experimental data demonstrating its potential anticancer activity in several cancer types including prostate cancer. Previous in vitro and in vivo studies have focused mainly on anti-oxidative effects as the underlying anticancer mechanism of VK. However, recent studies reveal that VK inhibits the growth of cancer cells through other mechanisms, including apoptosis, cell cycle arrest, autophagy, and modulation of various transcription factors such as Myc and Fos. In the present review, we focus on the anticancer effect of dietary VK and its analogs on prostate cancer, with an emphasis on the signaling pathways that are activated following exposure to these compounds. This review also highlights the potential of VK and its derivatives as an adjuvant treatment in combination with other vitamins or with chemotherapeutic drugs. Based on our recent results and a review of the existing literature, we present evidence that VK and its derivatives can potentially be explored as cancer therapy, especially for prostate cancer.
KEYWORDS:
Vitamin K; apoptosis and autophagy; dietary constituents; prostate cancer
PMID: 28915711 PMCID: PMC5593683 DOI: 10.18632/oncotarget.17997